Eye Medication News
|Quixin (Levofloxacin) Anti-Infective Ophthalmic Solution To Be Available In US |
OSAKA, JAPAN -- October 23, 2000 -- Santen Pharmaceutical Co., Ltd. (President and CEO: Takakazu Morita; Headquarters: Osaka, Japan), is pleased to announce that it has begun shipment to wholesalers and retailers of a new ocular anti-infective medication, Quixin (levofloxacin ophthalmic solution) 0.5%, indicated for the treatment of bacterial conjunctivitis. Santen's Napa, California-based subsidiary, Santen Incorporated, will market the product in the rapidly growing US$150 million ocular anti-infective segment.
|Azeltine Eye Drops Effective In Treating Allergic Conjunctivitis |
SAN FRANCISCO, CA -- December 1, 2000 -- Results from a study published in the December issue of Ophthalmology, the clinical journal of the American Academy of Ophthalmology, show azelastine eye drops (AZE) were highly effective in treating allergic conjunctivitis or eye allergies.
|ACAAI: Nedocromil Sodium Improves Allergic Conjunctivitis |
By Jill Stein
Special to DG News
SEATTLE, WA -- November 5, 2000 -- Nedocromil sodium 2% used twice daily is effective and safe for the treatment of symptoms in patients with allergic conjunctivitis, researchers report.
|ACR: Topical Cyclosporin A Restores Clear Vision To Sjogrens Syndrome Patients |
By Maria Bishop
Special to DG News
PHILADELPHIA, PA -- November 3, 2000 -- The signs and symptoms of keratoconjunctivitis sicca - a dry-eye condition - can be reversed with cyclosporin A, helping to reduce a common problem for patients with Sjogrens syndrome, stated researchers at the 64th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Philadelphia, Pennsylvania.
|FDA Approves Quixin (levofloxacin) For Bacterial Conjunctivitis |
OSAKA, JAPAN -- August 21, 2000 -- Santen Pharmaceutical Co., Ltd., announced that the U.S. Food and Drug Administration (FDA) has approved its new ocular anti-infective medication, Quixin (levofloxacin ophthalmic solution) 0.5%, indicated for the treatment of bacterial conjunctivitis.
The New Drug Application (NDA) was submitted to the FDA on March 1, 2000 by Santen Incorporated, Santen's Napa, California based subsidiary. The company anticipates the launch of Quixin in the U.S. ophthalmic market by late 2000.
Quixin is a sterile topical ophthalmic solution containing 0.5% levofloxacin, a potent, broad spectrum fluoroquinolone. Levofloxacin's higher solubility, at neutral pH, allows Quixin to be formulated at a higher concentration of active drug compared to other currently marketed ophthalmic fluoroquinolones (0.5% vs. 0.3%).
Bacterial conjunctivitis, commonly known as "pink eye," is a prevalent condition characterized by redness of the eye, mucous discharge, tearing, irritation and sensitivity to light. Quixin has shown outstanding efficacy against a wide range of causative organisms, including the most common gram-positive and gram-negative pathogens, Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae.
In controlled clinical trials in which bacterial conjunctivitis patients were dosed for 5 days, Quixin demonstrated excellent clinical and microbial efficacy; 79 percent of patients experienced clinical cure and microbial eradication rates were 90 percent. With an active drug concentration of 0.5% and powerful bactericidal properties, Quixin topical therapy rapidly resolves the signs and symptoms of bacterial conjunctivitis.
© 1998-2000 EyeSearch.com, Inc. Contact EyeSearch.com